LGVNHIGH SIGNALFINANCIAL10-K

LGVN experienced severe financial deterioration with cash plummeting 76% to $4.7M while R&D expenses surged 48% and losses deepened 42%.

The company faces immediate liquidity concerns as cash burned from $19.2M to $4.7M while operating losses widened significantly to $22.7M annually. With current liabilities increasing 58% and minimal revenue generation, LGVN appears to be approaching a critical funding inflection point that could force dilutive equity raises or operational restructuring.

Comparing 2026-03-17 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

LGVN's financial position deteriorated dramatically across all key metrics, with cash and total assets declining approximately 60-76% while losses expanded substantially. Revenue dropped 42% to just $709K while R&D spending increased 48% to $12M, creating an unsustainable burn rate that decimated the balance sheet. The combination of rising liabilities, shrinking assets, and accelerating losses signals acute financial distress requiring immediate capital infusion to maintain operations.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-75.8%
$19.2M$4.7M

Cash declined 75.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
-74.1%
$21.9M$5.7M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-72.2%
$19.6M$5.5M

Current assets declined 72.2% — monitor working capital adequacy and short-term liquidity.

Capital Expenditure
Cash Flow
-62.6%
$655K$245K

Capex reduced 62.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Assets
Balance Sheet
-59.9%
$25.6M$10.3M

Total assets contracted 59.9% — asset sales, write-downs, or balance sheet optimization underway.

Current Liabilities
Balance Sheet
+58.3%
$2.6M$4.1M

Current liabilities surged 58.3% — significant near-term obligations; verify ability to meet short-term debt.

Gross Profit
P&L
-57.4%
$1.9M$803K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

R&D Expense
P&L
+48%
$8.1M$12.0M

R&D investment increased 48% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-42.1%
-$16.0M-$22.7M

Net income declined 42.1% — review whether driven by operations, interest costs, or non-recurring items.

Revenue
P&L
-42%
$1.2M$709K

Revenue declined 42% — significant demand weakness or market share loss warrants investigation.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-02-28
ADDED
As of March 9, 2026, the registrant had 21,783,749 shares of Class A common stock, $0.001 par value per share, and 1,484,005 shares of Class B common stock, $0.001 par value per share, outstanding.
Such forward-looking statements can involve substantial risks and uncertainties.
Moreover, we operate in a very competitive and rapidly changing environment.
Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, circumstances or otherwise occurring after the date this 10-K is filed.
Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B .
+7 more — sign up free →
REMOVED
As of February 17, 2025, the registrant had 13,473,898 shares of Class A common stock, $0.001 par value per share, and 1,454,005 shares of Class B common stock, $0.001 par value per share, outstanding.
This 10-K contains forward-looking statements that can involve substantial risks and uncertainties.
We operate in a highly competitive and rapidly changing environment; therefore, new risk factors can arise, and it is not possible for management to predict all such risk factors, nor to assess the impact of all such risk factors on our business or the extent to which any individual risk factor, or combination of risk factors, may cause results to differ materially from those contained in any forward-looking statement.
We do not undertake any obligation to update these statements to reflect events or circumstances occurring after the date this 10-K is filed.
The Company s lead investigational product is Lomecel-B , an allogeneic Mesenchymal Stem Cell ( MSC ) formulation sourced from the bone marrow of young, healthy adult donors.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →